PRCM
AMBI

Pine River Capital Management’s Ambit Biosciences Corp AMBI Stock Holding History

Pine River Capital Management’s Portfolio AMBI Stock Details AMBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-174,100
Closed -$1.22M – 568
2013
Q2 		$1.22M Buy
+174,100
New +$1.24M 0.02% 354

Other funds holding AMBI

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pine River Capital Management's AMBI Position: Q3 2013 in Review

Pine River Capital Management sold out of Ambit Biosciences Corp (AMBI) in Q3 2013, closing a stake of 174,100 shares — an estimated $1.22M sold.

Pine River Capital Management first reported a position in AMBI in Q2 2013 and held it in 1 quarter. The position peaked at $1.22M in Q2 2013. 23 funds tracked by Wall St. Rank hold AMBI as of Q3 2013.

  • Pine River Capital Management reported no remaining Ambit Biosciences Corp position as of Q3 2013 after selling out during the quarter.
  • Pine River Capital Management sold 174,100 Ambit Biosciences Corp shares in Q3 2013, an estimated $1.22M.
  • Pine River Capital Management first reported a position in Ambit Biosciences Corp in Q2 2013 and held it in 1 quarter.
  • Pine River Capital Management's Ambit Biosciences Corp position peaked at $1.22M in Q2 2013.
  • 23 funds tracked by Wall St. Rank held Ambit Biosciences Corp as of Q3 2013.

Based on Pine River Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.